Emerald Health Therapeutics and Emerald Health Naturals on track to launch endocannabinoid-supporting products in Canada
Emerald
Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) today
announced that its joint venture partner, San Diego-based Emerald Health
Bioceuticals (“EHB”), has launched its award-winning Endo products in
Whole Foods Markets across the United States, highlighting the unique
positioning and opportunity for this product line when it is launched in
Canada in 2019. The joint venture, called Emerald Health Naturals
(“EHN”), secured Canadian distribution rights for this product line that
was developed to support the body’s endocannabinoid system (ECS), but
which does not contain cannabis. Canadian retailers have not been
announced.
In December 2018, EHT received
natural product numbers (NPNs) from Health Canada to sell Endo in
Canada. EHN is owned 51% by Emerald and 49% by EHB.
“For
the Endo products to be embraced by retailers with such high standards
of retail excellence and broad reach like Whole Foods Market in the US
is an important milestone for this unique natural health supplement
line,” said Gaetano Morello, ND, CEO of Emerald Health Naturals. “A
non-cannabis product line capable of nurturing the endocannabinoid
system is a unique product category - and it is one that is garnering
significant attention in the US. We aim to similarly build strong
distribution channels with top retailers in Canada in 2019.”
“With
60% of cannabis users also being users of natural health products, we
have a two-pronged opportunity in Canada to build a stand-alone market
for the Endo product line for cannabis non-users as well as achieve
Emerald brand recognition among cannabis users in channels unable to
carry cannabis products,” said Avtar Dhillon, President and Executive
Chairman, Emerald Health Therapeutics. “Natural health product stores,
pharmacies, and even grocery stores may all be potential outlets for the
Endo product line. We look forward to offering the proprietary Endo
products to Canadian consumers this year.”
Endo
nutritional supplements feature PhytoCann-Complex™, a proprietary
formulation consisting of non-cannabis, non-psychoactive, plant-based
bioactive compounds that support the body’s endocannabinoid system. The
role of the ECS as the body’s innate balancing mechanism is key to the
regulation of everything from appetite, energy, metabolism, fertility
and immunity to sleep, mood, pain perception and memory. The Endo
product line includes Endo Brain, Endo Sleep, Endo Calm, Endo Bliss and
Endo Inflame, and they are intended to naturally address the body’s
response to conditions such as stress, anxiety, restless sleep and pain,
and foster overall health and wellness.
Over
the last year, EHB has secured multiple distribution and sales channels
for the Endo product line in the United States and internationally,
ranging from small independent natural health product retailers to
nationwide grocery store chains like Whole Foods Market, as well as
Amazon.com.
About The Endo Product Line*
Endo Brain - Naturally supports mental acuity and cognition by nurturing and nourishing your endocannabinoid system.
Endo Brain - Naturally supports mental acuity and cognition by nurturing and nourishing your endocannabinoid system.
Endo Sleep - Enjoy restful and rejuvenating sleep by naturally supporting your endocannabinoid system, optimal health and vitality.
Endo Calm - Naturally
address your body’s response to stress and anxiety by supporting your
endocannabinoid system and optimal health and vitality.
Endo Bliss - Naturally supports a positive outlook and resistance to daily pressures by nurturing and nourishing your endocannabinoid system.
Endo Inflame - Naturally promote your body’s healthy response to pain and inflammation by supporting your endocannabinoid system for optimal health and vitality.
* The statements made herein have not been evaluated by Health Canada or the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Endo Inflame - Naturally promote your body’s healthy response to pain and inflammation by supporting your endocannabinoid system for optimal health and vitality.
* The statements made herein have not been evaluated by Health Canada or the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
About Emerald Health Therapeutics, Inc.
Emerald
Health Therapeutics, Inc. is a Canadian licensed producer of cannabis.
Its 50%-owned Pure Sunfarms joint venture in BC is completing the
conversion of its 1.1 million square foot (25 acre) greenhouse for
cannabis cultivation in the Lower Mainland and its Verdélite operation
in Québec is completing the build out of its 75,000 square feet indoor
cultivation facility. Commercial production is expanding in both
facilities. Emerald secured over 500 acres of hemp harvest in 2018 and
has contracted for approximately 1000 acres in 2019 to 2022, with the
objective of extracting low-cost cannabidiol (CBD). Emerald’s team is
highly experienced in life sciences, product development, large-scale
agri-business, and marketing, and is focused on developing proprietary,
value-added cannabis products for medical and adult-use customers.
Emerald is part of the Emerald Health group, which represents a broad
array of companies focused on developing pharmaceutical, botanical, and
nutraceutical products developed to provide wellness and medical
benefits by interacting with the human body’s endocannabinoid system.
No comments:
Post a Comment